Global Cardiovascular Therapeutic Drugs Market is segmented By Disease (Hypertension, Cardiac arrhythmias, Arteriosclerosis, Acute Coronary Syndrome, Myocardial infarction, Thrombosis, Hyperlipidemia, others) By Drug class(Anti-hypertensives, Anti-hyperlipidemias, Anti-arrhythmic, Anti-coagulants, Anti-fibrinolytics), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Size
The Global Cardiovascular Therapeutic Drugs Market reached USD 161.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 229.3 billion by 2031. The global cardiovascular therapeutic drugs market is expected to exhibit a CAGR of 4.6% during the forecast period 2024-2031. The cardiovascular therapeutic drugs market is a rapidly growing sector that focuses on medications for treating cardiovascular diseases.
It encompasses a wide range of drugs, including anticoagulants, antiplatelet agents, beta-blockers, ACE inhibitors, statins and more. The high prevalence of cardiovascular diseases, such as heart disease and stroke driving the market globally.
Increasing awareness about cardiovascular health, advancements in drug development and a growing aging population contribute to market growth. The global cardiovascular therapeutic drugs market is driven by factors such as the increasing prevalence of cardiovascular diseases, the rising aging population, technological advancements in cardiovascular therapeutics, increasing research and innovations for efficient drug development, unhealthy lifestyle choices and increasing awareness and focus on preventive care.
Market Summary
| Metrics | Details |
| CAGR | 4.6% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Disease Type, Drug Class and Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Request Free Sample
Market Dynamics
Increasing Awareness and Focus on Preventive Care Drive the Growth of the Cardiovascular Therapeutic Drugs Market
The increasing awareness and focus on the preventive care of cardiovascular diseases is a major factor expected to drive the market share during the forecast period. There is a growing emphasis on preventive healthcare, including lifestyle modifications and early intervention to prevent cardiovascular diseases. This awareness has led to greater demand for medications that can help manage risk factors and prevent the onset or progression of cardiovascular conditions.
The cardiovascular therapeutic drugs market experiences growth due to the rising demand for medications that can help prevent, manage and treat cardiovascular diseases. These medications include statins for cholesterol management, antiplatelet agents for preventing blood clots and anti hypertensive drugs to control blood pressure. Additionally, pharmaceutical companies and healthcare providers often collaborate to promote awareness campaigns, education programs and screening initiatives.
For instance, in March 2023, Evermed and the American College of Cardiology (ACC) announced the launch of ACC Anywhere, a new content hub that provides cardiologists around the world with on-demand access to the latest clinical knowledge and awareness about the prevention of cardiovascular diseases. The hub contains original content from five conferences including ACC’s 2022 and 2023 Annual Scientific Session, with additional conferences to be added in the future.
Increasing Research and Innovations for Efficient Drug Development Drive the Growth of the Market
The increasing research and innovations for efficient drug development is also a major factor expected to drive the cardiovascular therapeutic drugs market. Extensive research efforts focus on identifying new molecular targets and pathways involved in cardiovascular diseases. These discoveries enable the development of innovative drug candidates that specifically target these mechanisms, leading to more effective treatments.
Research and innovation facilitate the development of advanced drug delivery systems, such as sustained-release formulations and targeted drug delivery platforms. These advancements enhance the pharmacokinetics, bioavailability and patient compliance of cardiovascular drugs, improving their therapeutic efficacy.
For instance, in February 2023, Cardio Diagnostics Holdings Inc., an artificial intelligence-powered precision cardiovascular medicine company, announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Adverse Effects Associated with Drugs Will Hamper the Growth of the Market
The adverse effects associated with cardiovascular therapeutic drugs are a major factor expected to hamper market growth. Adverse effects can negatively impact patient compliance and adherence to prescribed medications. Patients may be reluctant to continue or initiate treatment if they experience unpleasant side effects. This can lead to suboptimal disease management and lower demand for cardiovascular drugs, affecting market growth.
Adverse effects can raise safety concerns among healthcare professionals, patients and regulatory authorities. Reports of severe side effects can lead to regulatory scrutiny, resulting in increased safety assessments and stringent regulations for drug approval. This can prolong the drug development process and limit market entry.
Market Segment Analysis
The global cardiovascular therapeutic drugs market is segmented based on disease type, drug class, distribution channel and region.
Owing to Prevalence, the Hypertension Segment Accounted for Approximately 34.9% of the Cardiovascular Therapeutic Drugs Market Share
The market is anticipated to grow throughout the projection due to the sector known as hypertension. Hypertension is a chronic condition that often requires long-term management. Patients with hypertension generally require ongoing medication to control and maintain their blood pressure within the normal range. The continuous use of antihypertensive drugs leads to a consistent demand for the medications.
Hypertension is one of the predominant risk factors for the development of several cardiovascular diseases and affects a large number of individuals. The increasing prevalence of hypertension is primarily attributed to factors such as sedentary lifestyles, unhealthy diets, obesity and aging populations. The high disease burden drives the demand for antihypertensive medications, making the hypertension segment dominant in the market.
For instance, in May 2023, ATCOR Medical, a subsidiary of CardieX and developer of innovative medical devices and digital health solutions to optimize hypertension management and improve clinical trial patient outcomes, announced it has launched a single-center retrospective study of 2,000 hypertensive patients to identify associated care outcomes resulting from the routine monitoring of central aortic blood pressure (cBP) and peripheral blood pressure (pBP).
Market Geographical Share
North America Accounted for Approximately 38.7% of the Market Share in 2022, Owing to the Introduction of New Drugs and the High Prevalence of Cardiovascular Diseases
North America, particularly the United States, has a robust pharmaceutical industry that actively introduces new cardiovascular drugs to the market. Pharmaceutical companies in the region invest heavily in research and development, leading to the discovery and approval of innovative drugs for cardiovascular diseases. The continuous introduction of new drugs enhances treatment options and drives market growth in the region.
North America has a high prevalence of cardiovascular diseases, including heart disease, stroke and hypertension. Factors such as sedentary lifestyles, unhealthy diets and an aging population contribute to the increased disease burden in the region. The high prevalence necessitates a substantial demand for cardiovascular therapeutic drugs, leading to a larger market share.
Market Players
The major global players in the cardiovascular therapeutic drugs market include Abbott Laboratories, AstraZeneca, Pfizer Inc, Novartis, Bristol Myer Squibb, Bayer, Merck, Sanofi, Boehringer Ingelheim, Roche and others.
COVID-19 Impact on Cardiovascular Therapeutic Drugs Market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global cardiovascular therapeutic drugs market. Regulatory authorities may prioritize other urgent matters, leading to delays in drug approvals or changes in regulatory requirements. These challenges can hamper the timely introduction of new cardiovascular drugs to the market.
The conflict may disrupt research and development collaborations between institutions and companies in Russia, Ukraine and other countries. Collaboration is crucial for advancing cardiovascular drug development and any disruption can hinder progress and innovation in the field.
Key Developments
- On May 8, 2023, Ucardia, a leading provider of virtual cardiac rehabilitation and recovery solutions, announced that it has reached an agreement to acquire Phas3, a pioneer in home-based cardiac rehab and fellow industry leader. This acquisition will result in a comprehensive, market-leading solution for providers, payers and consumers, covering all facets of cardiac rehabilitation, conditioning and remote monitoring for patients affected by cardiovascular disease (CVD).
- On June 05, 2023, NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease (“CVD”) with a residual elevation of low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, announced statistically significant and clinically meaningful topline results from the Phase 2b dose-finding trial of obicetrapib, the company’s oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor, as an adjunct to stable statin therapy in Japanese patients with dyslipidemia. Based on the results observed, NewAmsterdam plans to leverage data from the ongoing Phase 3 BROOKLYN, BROADWAY and PREVAIL clinical trials, if supportive, to pursue regulatory approval in Japan.
Why Purchase the Report?
- To visualize the global cardiovascular therapeutic drugs market segmentation based on disease type, drug class, distribution channel and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of cardiovascular therapeutic drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global cardiovascular therapeutic drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
